Urocortin II, human TFA 

Urocortin II, human TFA is a selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor. Urocortin II, human TFA has an effect of promoting satiet and neuroprotective effect. Urocortin II, human TFA also has bactericidal, antiparasitic and pro-inflammation activity. Urocortin II, human TFA can activate NF-κB pathway and ERK1/2 MAP kinase. Urocortin II, human TFA can reduce pulmonary arterial hypertension and shows cardiac protection effect. Urocortin II, human TFA can be used for the researches of infection, inflammation, metabolic, neurological and cardiovascular disease^{[1][2][3][4][5]}.

Urocortin II, human TFA shows bactericidal activity against E. coli, P. pseudoalcaligenes and M. luteus with EC₅₀ values of 2.81, 1.16 and 4.92 μM^[3].
Urocortin II, human TFA shows antiparasitic activity against L. major, L. tropica and L. infantum with EC₅₀ values of 9.20, 22.41 and 12.47 μM^[3].
Urocortin II, human TFA (0.1-1000 nM, 6-24 h) induces IL-8 mRNA and protein expression, activates the NF-κB pathway (IkBα degradation, p65 phosphorylation) and ERK1/2 MAP kinase in human colonic epithelial NCM460 cells overexpressing CRHR2α^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Urocortin II, human TFA (0.1-10 μg/mouse; i.c.v.; 30 minutes before the start of the dark) reduces the intake of foods and water and inhibit delayed movement in Wistar rats^[1].
Urocortin II, human TFA (2.5 μg/kg; i.p.; single dose) shows neuroprotective effect in intracerebral hemorrhage of rats^[2].
Urocortin II, human TFA (1 nM/mouse, i.p., administered at 1, 12, and 24 h after cecal ligation and puncture) improves survival rate, reduces bacterial load and inflammatory mediator levels in blood and peritoneal fluid, and alleviates tissue pathological damage in female BALB/c mouse models of sepsis^[3].
Urocortin II, human TFA (5 μg/kg, i.p., twice a day for 10 days) reduces pulmonary arterial hypertension, improves exercise capacity and attenuates pulmonary arterial and right ventricular remodelling and dysfunction in Monocrotaline (HY-0750)-induced rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

4152.89 (free base)

C₁₈₃H₃₂₄N₅₈O₅₁.xC₂HF₃O₂

Ile-Val-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Leu-Gln-Ile-Leu-Leu-Glu-Gln-Ala-Arg-Ala-Arg-Ala-Ala-Arg-Glu-Gln-Ala-Thr-Thr-Asn-Ala-Arg-Ile-Leu-Ala-Arg-Val-NH2

IVLSLDVPIGLLQILLEQARARAAREQATTNARILARV-NH2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zorrilla EP,et al. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity. J Pharmacol Exp Ther. 2004 Sep;310(3):1027-34.  [Content Brief]

  [2]. Liew HK, et al. Therapeutic effects of human urocortin-1, -2 and -3 in intracerebral hemorrhage of rats. Neuropeptides. 2015 Aug;52:89-96.  [Content Brief]

  [3]. Campos-Salinas J, et al. Protective role of the neuropeptide urocortin II against experimental sepsis and leishmaniasis by direct killing of pathogens. J Immunol. 2013 Dec 15;191(12):6040-51.  [Content Brief]

  [4]. Adão R, et al. Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.  [Content Brief]

  [5]. Moss AC, et al. Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. Gut. 2007 Sep;56(9):1210-7.  [Content Brief]